正在加载图片...
“二次打击”学说 FLT3-ITD PML/RARC FLT3 D835Y Associated with a block Confer proliferative and/or haematopoietic differentiation at survival advantage, but do not the promyelocyte stage, affect differentiation not sufficient to cause APl RX FLT3 inhibitors APL ATRA D. Gary Gilliland Best Practice& Research Clinical Haematology. 2003, 16. 409-417“二次打击”学说 D.Gary Gilliland Best Practice & Research Clinical Haematology.2003;16:409-417
<<向上翻页向下翻页>>
©2008-现在 cucdc.com 高等教育资讯网 版权所有